Medpace Holdings Inc. (MEDP), which reported strong financial results for the first quarter ended March 31, 2024, expects revenue for this year to grow in the range of 14.0% to 16.7%.
The company is a global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com